Matthew T. Wiley, Chief Commercial Officer of Definium Therapeutics, Inc. (NASDAQ:DFTX), filed a Form 4 on September 14, 2026, reporting the acquisition of 125,000 common shares through the vesting of performance share units.

Key Highlights

  • Transaction date: September 14, 2026, with 125,000 common shares acquired at a price of $0.00.
  • Source of shares: The shares represent the third tranche of performance share units granted effective March 17, 2025.
  • Continued vesting requirement: The shares remain subject to vesting based on continued employment through March 17, 2028.
  • Milestone basis: Each performance share unit represented a contingent right to receive one common share tied to the achievement of certain clinical and regulatory milestones.
  • Resulting ownership: Following the transaction, Wiley directly beneficially owns 362,133 common shares.

Wiley's Performance Share Unit Award Details at Definium Therapeutics

According to the filing, Matthew T. Wiley, serving as Chief Commercial Officer at Definium Therapeutics, Inc., reported the acquisition of 125,000 common shares on September 14, 2026. The transaction code is listed as "A" (acquired), and the shares were received at a price of $0.00, consistent with the settlement of performance share units rather than an open-market purchase.

The filing's footnote explains that the 125,000 common shares "represent the third tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028." The filing further states that each performance share unit "represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."

Following this reported transaction, Wiley's direct beneficial ownership in Definium Therapeutics common shares stands at 362,133 shares, as disclosed in Table I of the filing. The form was signed by Mark Sullivan as Attorney-in-Fact for Matthew T. Wiley and was filed as a report by one reporting person. No derivative securities activity was reported in Table II of the filing.

What Was Disclosed

Definium Therapeutics CCO Matthew T. Wiley filed a Form 4 disclosing the acquisition of 125,000 common shares at $0.00 on September 14, 2026, representing the third tranche of a March 17, 2025, performance share unit grant, with further vesting contingent on continued employment through March 17, 2028.